Genmab A (GMAB) Non-Current Debt (2022 - 2026)

Genmab A (GMAB) has reported Non-Current Debt for 5 consecutive years, with $4.8 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Debt changed N/A year-over-year to $4.8 billion; the trailing twelve-month figure through Jun 2026 stood at $4.8 billion (changed N/A YoY), and the FY2025 full-year result was $5.0 billion, up 3550.36% from the prior year.
• Non-Current Debt advanced to $4.8 billion in Q2 2026 per GMAB's latest filing, from $4933.0 in the prior quarter.
• Across five years, Non-Current Debt topped out at $5.0 billion in Q4 2025 and bottomed at $4933.0 in Q1 2026.
• Historically, Non-Current Debt has averaged $1.7 billion across 5 years, with a median of $90.4 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Non-Current Debt gained 1.43% in 2024, then jumped 5395.88% in 2025.
• Over 5 years, Non-Current Debt stood at $74.6 million in 2022, then rose by 20.33% to $89.7 million in 2023, then gained by 1.43% to $91.0 million in 2024, then surged by 5395.88% to $5.0 billion in 2025, then declined by 3.2% to $4.8 billion in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $4.8 billion, $4933.0, and $5.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.